Urology | Home | MIMS Malaysia

ADT-AAP combo effective for metastatic prostate cancer

2 hours ago

The combination of androgen deprivation therapy (ADT) with abiraterone acetate and prednisolone (AAP) treatment is effective against metastatic hormone-naïve prostate cancer (mHNPC) regardless of risk stratification, a recent study has shown.

Smoking at home, during teenage years up risk of death from bladder, kidney cancers

22 hours ago

Smoking intensity is associated with mortality from genitourinary malignancies, according to a nationally representative study. Moreover, the risk of death from bladder and kidney cancers is significantly higher among individuals who started smoking at a younger age and those who smoke at home.

Skeletal muscle, fat mass indexes predict discharge to facility after radical cystectomy

Yesterday

Low skeletal muscle and high fat compositions are independently associated with discharge to a facility following radical cystectomy of nonmetastatic muscle invasive bladder cancer, a study has found.

High animal protein intake ups risk of incident kidney stones

Yesterday

Higher consumption of animal protein appears to increase the risk of developing kidney stones, according to a study involving a population with a relatively low animal protein intake and a high plant protein intake in Shanghai, China. Increasing the proportion of plant relative to animal protein may protect against this risk.

Original New Drug Application Approvals by US FDA (01 - 15 November 2019)

5 days ago

New drug applications approved by US FDA as of 01 - 15 November 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Uroselective α1A-AR antagonist: A promising agent for the management of BPH

15 Mar 2019

At the Eisai-sponsored tea symposium during the 27th Malaysian Urological Conference at Shangri-La Kuala Lumpur, Professor Osamu Yokoyama highlighted the advantages of silodosin (Urief®, Eisai Inc.) in relieving lower urinary tract symptoms associated with benign prostate hyperplasia.

Immunotherapy promising treatment option for metastatic castrate-resistant prostate cancer

Pank Jit Sin, 03 Sep 2019

Immunotherapy, in the setting of advanced prostate cancer (PCa), may alter the lethal condition of advanced PCa into a chronic disease with significantly longer overall survival (OS), says an expert.

Research sheds light on PARP inhibitor use in mCRPC

Jackey Suen, 06 Mar 2019

The future of poly(adenosine diphosphate–ribose) polymerase (PARP) inhibitors in the treatment of metastatic castration-resistant prostate cancer (mCRPC) is promising in light of encouraging results from recent clinical studies.

Immune-checkpoint inhibitors changing the landscape of bladder cancer management

Dr. Joseph Delano Fule Robles, 04 Mar 2019

Since the approval of immune checkpoint inhibitors (ICIs) as standard of care in the second-line setting for metastatic urothelial carcinoma, new approaches on how clinicians manage this condition are emerging.

Robot-assisted radical cystectomy comparable to open cystectomy for urologic cancers

Dr. Joseph Delano Fule Robles, 22 Feb 2019

Studies have demonstrated that robot-assisted radical cystectomy (RARC) is as effective and has a cost advantage compared with open cystectomy for the management of urologic cancers.

Prostate cancer biomarker research gains momentum, but challenges remain

Jackey Suen, 30 Jan 2019

Recent research has revealed various potential biomarkers for metastatic castration-resistant prostate cancer (mCRPC), but several challenges remain in fully utilizing them in clinical practice.

Nanotechnology structured water shows potential for ED treatment

Audrey Abella, 11 May 2018

Nanotechnology structured water was similarly effective as tadalafil in improving erectile function, suggesting that it could be a potential treatment option for erectile dysfunction (ED), according to a study presented at EAU held in Copenhagen, Denmark.

Vibegron shows potential as OAB treatment

Audrey Abella, 30 Apr 2018

The selective β3-adrenoreceptor (AR) agonist vibegron showed superior efficacy over placebo for overactive bladder (OAB) treatment and was generally well-tolerated, according to a Japanese study presented at EAU 2018.